You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Photo-mediated ultrasound therapy for treatment of cutaneous vascular malformations

    SBC: Photosonox LLC            Topic: NIBIB

    ABSTRACT: Cutaneous vascular malformations (CVM), such as port wine stain (PWS) which occurs in 0.3–0.5% of newborns, are often a cause of great concern to patients for both medical and cosmetic reasons. Laser irradiation with flashlamp-pumped pulsed dye lasers, i.e. photothermolysis therapy (PTT), is currently the gold standard treatment for PWS. Most patients with PWS, however, fail to clear c ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. InheRET: A SaaS solution to identify patients at increased risk for hereditary disease.

    SBC: Inheret, Inc            Topic: NCI

    PROJECT SUMMARY This project is to expand the InheRET Inherited Risk Evaluation Tool to include recommendations for testing of patients at increased risk for hereditary disease, adding patient navigation features and customizable database entries for healthcare providers. This will include the development, integration and testing of InheRET 3.0 followed by pilot testing in 5 diverse clinics. InheR ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Cerenkov Multi-Spectral Imaging (CMSI) for Adaptation and Real-Time Imaging in Radiotherapy

    SBC: Endectra LLC            Topic: 102

    PROJECT SUMMARY Understanding of tumor molecular characteristics during a course of radiotherapy (RT) treatment is crucial to assess the efficacy of the treatment and adapt radiation dosage to optimize outcomes. Unfortunately, this cannot be routinely achieved by current diagnostic nuclear imaging modalities due to complex logistics and prohibitive costs. Alternatively, Cerenkov Emission (CE) is a ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD

    SBC: ONL Therapeutics, Inc.            Topic: NEI

    PROJECT SUMMARY / ABSTRACT Age-related macular degeneration (AMD) is the leading, and due to the aging baby boomers, a growing cause of irreversible vision loss in the United States, and is strongly associated with exposure to cigarette smoke (CS) and high fat diets (HFD). While effective treatment is available for neovascular AMD, the AREDS II antioxidant vitamins are the only proven treatment fo ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Vaccination against Zika virus infection using mosquito NeSt1 protein

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    Arthropod-borne viruses (arboviruses) present a substantial threat to human and animal health worldwide. They are transmitted by hematophagous arthropods, in which mosquitoes are one of the main transmitters. The mosquito specie, Aedes aegypti, is the primary mosquito vector of several widely spread arboviruses as zika, dengue or West Nile viruses. Mosquitoes transmit these pathogens by inoculatin ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Low Visibility Radio Frequency Resonator

    SBC: VIRTUAL EM INC.            Topic: SOCOM19A001

    A prototyping effort is being proposed to develop methods and tools for utilizing structures of opportunity as efficient radiations in the HF, VHF and UHF bands.

    STTR Phase II 2020 Department of DefenseSpecial Operations Command
  7. Stress forces huESC differentiation; confirmation as an accurate DevTox HTS

    SBC: Reproductive Stress; Measurement, Mechanisms and Management, Corp.            Topic: R

    EXECUTIVE SUMMARY - huESC HTS2 - human Toxic stress effects in 1st trimester pregnancy leads to $10s of billions of US health care costs/year and is a significant part of the $2.5-4B/year US Developmental and Reproductive Technology (DART industry. Current DART techniques use slow, expensive pregnant rodent tests, or tests of embryonic stem cells (ESCs) that are cultured to lose “stemness” and ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a tool to examine proteomic pathways in the AD brain

    SBC: ProteoWise Inc.            Topic: NIA

    Abstract For the extent of our careers as Alzheimer’s researchers, we have struggled with the limitations imposed by the standard techniques for protein analysis. Western blot, the go-to protein technology of the bench researcher, is no match for the complex brain protein distortions of AD. To remedy this debility, we devised a technology that we are making available to all researchers through t ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. An augmented reality platform to reduce post-operative and chronic opioid use in pediatric cancer

    SBC: ALTALITY, INC.            Topic: NIDA

    PROJECT SUMMARY/ABSTRACT Pediatric opioid use is a public health crisis. In children, prescription opioids are the primary source of non- medical abuse as well as opioid-associated hospitalizations and deaths. Early opioid use in childhood is a known “gateway” to adulthood dependence and substance abuse disorders. Despite years of research, opioids remain the most commonly prescribed pain medi ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Nanosecond Laser and Ultrasound to Selectively Treat Eye Blood Vessels

    SBC: Photosonox LLC            Topic: NEI

    ABSTRACT / PROJECT SUMMARY Wet age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. Anti-VEGF therapy is currently the gold standard for wet AMD treatment. However, up to 50% of patients in the long term have a suboptimal response to anti-VEGF therapy. A better alternative method for treatment of AMD is urgently needed. We have recently inve ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government